At the macro level, the first half of 2024 saw two U.S. Senators propose bills attempting to regulate private equity’s involvement in the healthcare industry while the U.S. Federal Trade Commission aggressively targeted private equity for its role in healthcare. There was also an influx of new state legislation, including efforts to directly restrict private equity investment, but many efforts failed to pass this legislative term. This Holland & Knight alert provides a mid-year review of the ongoing federal and state scrutiny focused on private equity investments in the healthcare industry and what investors and platform companies can expect for the rest of the year.
Read the full article: Healthcare Private Equity Transactions under Scrutiny: Mid-Year Review //
Source: https://www.hklaw.com/en/insights/publications/2024/08/healthcare-private-equity-transactions-under-scrutiny-mid-year-review